BMAL1 and neoplasm: According to past works, Bmal1 can act as a potent anti-oncogene in PDAC by activating the downstream p53-dependent tumor suppressor pathway [68], this component being considered an independent prognostic factor for tumor progression and poor survival outcome for patients with PDAC [69].